Clinical Trial Detail

NCT ID NCT02677948
Title Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors University of Michigan Cancer Center
Indications

CLL/SLL

Therapies

Ibrutinib + Pacritinib

Age Groups: adult

No variant requirements are available.